Table 3. Compound effect on OPC differentiation in cultures of mixed glial cells.
| Compound | MBP RNA level (Mean ± SE) | p-value | CGT RNA level (Mean ± SE) | p-value |
|---|---|---|---|---|
| CTR | 1 ± 0 | — | 1 ± 0 | — |
| T3 + T4 | 2.85 ± 0.45 | 0.01 | 2.65 ± 0.9 | 0.09 |
| VULPINIC ACID | 1.72 ± 0.49 | 0.1075 | 1.34 ± 0.47 | 0.2549 |
| LOVASTATIN | 2.84 ± 0.53 | 0.0127 | 1.78 ± 0.18 | 0.006 |
| METHOXYISOFLAVONE | 2.32 ± 0.5 | 0.039 | 1.97 ± 0.34 | 0.051 |
| EDARAVONE | 3.86 ± 0.39 | 0.0009 | 2.76 ± 0.58 | 0.0197 |
| CHLORMADINONE ACETATE | 3.12 ± 0.57 | 0.0101 | 2.35 ± 0.56 | 0.037 |
| LOSARTAN | 2.38 ± 0.63 | 0.0467 | 2.8 ± 0.57 | 0.0532 |
| FENAMISAL | 2.78 ± 0.76 | 0.0726 | 1.38 ± 0.22 | 0.1106 |
The 7 selected compounds were screened for their ability to stimulate OPC differentiation in cultures of mixed glial cells. Cells were treated with compounds (10 μM) or DMSO (0.001% vehicle) for 48 h and the expression of CGT and MBP mRNA was evaluated by real time RT-PCR. The results show that 5 out of 7 compounds significantly (p < 0.05) stimulated the expression of both MBP and CGT genes compared to untreated control. 5-methyl-7-methoxyisoflavone is abbreviated as methoxyisoflavone. Data are expressed as 2−ΔΔCt value relative to untreated control, using GAPDH as reference gene. T3 (30 ng/ml) and T4 (40 ng/ml) were used as positive control.